Hennick Bridgepoint Hospital, Sinai Health’s Post

We're excited to be presenting the 2024 Global NF Conference! If you're attending, come and meet us and see what we're up to. And in addition to several research posters from our team, we're putting on two free 90min workshops for attendees: The first will show researchers how to access, analyze and reuse datasets from our NF Data Portal. Want to see how you can repurpose these data for your own research? Register here: https://lnkd.in/g7VYyybf The second will offer folks hands-on experience on using generative AI to extract data and curate scientific literature. Want to learn to use LLMs to get the most our of journal articles? Register here: https://lnkd.in/gAUCs86p #EndNF #nfresearch #raredisease #neurofibromatosis Children's Tumor Foundation

https://lnkd.in/eFZGvaVF Fantastic science and it clearly demonstrates what lies ahead in this remarkable field of bio-technology. I found it curious that the authors felt that its use could be for those in definite high risk groups. We all know that the issue with PCA is that, by and large (despite being ‘rare’) it presents to the patient and primary care doctor at a very advanced stage ( for a myriad of reasons) and my own humble conscience tells me that (on the basis they dismiss high cost) this is a test for “all seasons” (even with the additional Ca-19-9 blood test) and for anyone over a certain age and presenting with vague upper abdominal pain and a normal endoscopy to exclude other more common causes. Maybe they are being professionally conservative (as scientists often are, justly so) but this technology demands huge funding to look at the clinical utility across the range of all adults over 45 ( we can argue about the cut offs in due course).  Pancreatic Cancer is generally an abysmal diagnosis. Let’s utilise our energies and opportunities to change that depressing fact. Unaltered for decades. Please, let’s define an affordable screening strategy. A Nobel prize awaits. At least…

We are excited to announce that our work in collaboration with James Monkman, Afshin Moradi, Joseph Yunis, Rahul Ladwa, Ken O-Bryne, and Arutha Kulasinghe, as well as Enable Medicine team members Geoff Ivison and Aaron Mayer is now published in The Journal of Translational Medicine. Using an #analysispipeline to #phenotype and profile spatial features and interactions in #NSCLC patients that subsequently received #PD1 axis #immunotherapy, the study: - Found that #spatial localization of immune cells within tumors is key to understanding intercellular communications that can dictate #clinicaloutcomes. - Showcased the ability to delineate both tumor and immune cell phenotypes, infer their functional properties, and measure how their changes can associate with patient outcomes. Read the full study below: https://hubs.li/Q02nhJrN0

New! 🐟 Exploring the impact of GSTM1 as a novel molecular determinant of survival in #headandneckcancer patients of #Africandescent --------------------- Blacks/African American (BAA) patients diagnosed with head and neck squamous cell carcinoma (HNSCC) have worse survival outcomes than White patients. However, the mechanisms underlying racial disparities in HNSCC have not been thoroughly characterized. This study by YONG TENG et al identifies GSTM1 as a novel molecular determinant of survival in HNSCC patients of African descent. It also provides a molecular basis for future research focused on identifying molecular determinants and developing therapeutic interventions to improve outcomes for BAA patients with HNSCC. For free🎈 https://lnkd.in/dmeMgiRb #Genomicprofiling #Racialdisparities IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Joshua Mendell, M.D., Ph.D., and the Mendell Lab at UT Southwestern have identified an RNA molecule that regulates cellular senescence. This process can stop uncontrolled cell division to prevent tumors, but excessive senescence accelerates aging and degenerative diseases. Learn more about this key discovery that could lead to a host of new treatments. https://bit.ly/3YqKWAz

[Blog] Tumors represent intricate ecological systems in which diverse clonal subpopulations interact and co-evolve within the context of their microenvironmental niches. Recently published in Science Magazine and presented at #AACR24, our own Alex (Chieh-Yuan) Li dives into how the innovative Clonal Replica Tumors (CRTs) modeling was leveraged to study the clonal evolution of pancreatic ductal adenocarcinoma from primary lesion growth to overt disease dissemination Read it here ➡ https://lnkd.in/gXAczTMv #blog #diseasemodeling #solidtumor #oncologyresearch #singlecell #singlecellanalysis

🌟 Research Update! 🌟 Thrilled to share our latest findings on the role of adaptive immunity in Alzheimer's Disease. Here, we explore T cell responses at early (preclinical) and later stages of the pathology, offering fresh insights and a strong foundation for future research. Much more is coming on this topic in the next months. Stay tuned! 🔗Check out Chiara's post for the link to the full preprint. Your thoughts and feedback are always welcome! #AlzheimersResearch #AdaptiveImmunity #Neuroscience #Tcells

New research from the Icahn School of Medicine at Mount Sinai directly captured tumor microenvironment immune dynamics in the largest study of patients with relapsed/refractory multiple myeloma to date. The study analyzed the pharmacodynamic effects of iberdomide, an immunomodulatory therapy, to determine therapeutic efficacy and assist in establishing combination strategies using this treatment. The team developed and used a large-scale mass cytometry panel for immunophenotyping of bone marrow samples, correlating findings to disease characteristics, prior therapy, and a peripheral blood immune phenotype. Van Oekelen, O. et al. 2024: https://lnkd.in/gHdNVmNE #immunotherapy #cancerresearch #CyTOF

* 𝗖𝗥𝗜𝗦𝗣𝗥 𝗦𝗰𝗿𝗲𝗲𝗻𝘀 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝗩𝗶𝘁𝗮𝗹 𝗹𝗻𝗰𝗥𝗡𝗔𝘀 * American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than 700 lncRNAs necessary in specific contexts. The researchers at New York University explored how the loss of over 6,000 human lncRNAs impacted cellular fitness in HEK293FT and four cancer cell lines. The massively parallel screens utilised RNA-degrading CRISPR-Cas13 and 75,000 gRNAs to precisely knock down lncRNAs without disrupting DNA regulatory elements and thereby leaving nearby protein-coding genes unaffected. Read on at CRISPR Medicine News to learn about the study's results 👇 https://lnkd.in/dUdUUNPU #crisprmedicinenews #crisprmedicine #crispr #geneediting #genomeediting New York University New York Genome Center Neville Sanjana

📰 Excited to share that our own Dr. Dale Muzzey, PhD and Chief Scientific Officer, helped contribute to this insightful piece published by Inside Precision Medicine. This article sheds light on the critical advancements in Minimal Residual Disease (MRD) detection, a field that is helping transform #oncology and patient outcomes. We are committed to leading the way in #innovation and precision medicine - Thank you, Dr. Muzzey, for helping underscore our dedication to advancing MRD research and enhancing patient care. 🔗 Read the full article: #mrd #teamMyriad #cancercare